Loading...
| A04761 | Pages: 189 | Jul 2021 | 6724 Views | | |
| Author(s) : Vishal Bharadwaj , Onkar Sumant | Tables: 90 | Charts: 43 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Cancer Pain Market
Request Now !The global cancer pain market was valued at $6,197.8 million in 2020, and is estimated to reach $10,329.4 million by 2030, growing at a CAGR of 5.3% from 2021 to 2030.
The impact of COVID-19 pandemic is expected to remain moderate for the cancer pain market. The companies are facing a setback, owing to the lockdown, which led to a drop in the manufacturing and the patient flow reduced substantially. Also, the demand of cancer pain drugs further reduced due to the delayed shipments & production schedules which furthers create financial problems for companies with heavy debts. This, in turn, has limited the impact of COVID-19 on the cancer pain market.
Cancer pain can be due to the disease condition itself or may be due to the associated surgery, chemotherapy, and others. There are various drugs used for the management of cancer pain. The drugs used for the treatment of cancer pain depend on the severity of pain for instance strong opioids are used preferably in case of severe pain whereas non-opioids such as acetaminophen and NSAIDs are preferred to treat mild to moderate cancer pain.
Get more information on this report : Request Sample Pages
Growth of the global cancer pain market is majorly driven by increase in prevalence of cancer; rise in geriatric population; increase in healthcare expenditure; and increase in investments in R&D activities by various healthcare companies. For instance, according to American Cancer Society, nearly 1.8 million new cancer cases were diagnosed and about 606,520 cancer deaths were observed in the U.S. in 2020. According to the International Agency for Research on Cancer, in 2020, approximately 1,065,960 new cases were reported for colorectal cancer worldwide. The geriatric population is more vulnerable to various types of cancers, such as lung cancer, bladder cancer, renal cancer, melanoma, and others, due to aging effect and mutation in the gene. According to the National Cancer Institute, the median age for diagnosis is 61 years for breast cancer, 68 years for colorectal cancer, 70 years for lung cancer, and 66 years for prostate cancer. Furthermore, according to the Medicare and Medicaid Services, the National Health Expenditure (NHE) reached $3.8 trillion in 2019. The NHE increased by 4.6% in 2019, and accounted for 17.7% of the U.S. GDP. Surge in demand for monoclonal antibodies for the treatment of cancer boosts the growth of the cancer pain market.
However, adverse effect associated associated with the use of drugs employed in cancer pain management such as drug tolerance, drug dependence, urinary retention, sleep disorders, cognitive impairment, and others are expected to restrict the cancer pain market growth during the forecast period.
The cancer pain market is segmented on the basis of drug type, disease indication, and region. By drug type, the market is categorized into opioids, non-opioids, and nerve blockers. On the basis of opioids, it is further bifurcated into morphine, fentanyl, and others. By non-opioids, the market is divided into acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDS). By disease indication, it is divided into lung cancer, colorectal cancer, breast cancer, prostate cancer, blood cancer, and others.
Region wise, the cancer pain market is analyzed across North America (the U.S., Canada and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Depending on drug type, the opioids segment dominated the market in 2020, and is expected to continue this trend throughout the forecast period, owing to rise in prevalence of severe cancer pain, increase in adoption of opioids in the management of cancer pain, and strong presence of pipeline drugs. However, the non-opioids segment is expected to witness considerable market growth during the forecast period, owing to easy availability and lower cost of drugs.
Get more information on this report : Request Sample Pages
On the basis of disease indication, the lung cancer segment dominated the cancer pain market in 2020, and is expected to continue this trend throughout the forecast period, due to increase in prevalence of lung cancer, higher incidence of pain associated with lung cancer, and availability of effective cancer pain analgesic for the treatment of lung cancer. However, the breast cancer segment is expected to witness considerable market growth during the forecast period, due to increase in prevalence of breast cancer and higher adoption of pain analgesic in the treatment of breast cancer.
Get more information on this report : Request Sample Pages
North America accounted for a major share in the cancer pain market in 2020, and is expected to maintain its dominance during the forecast period, owing to rise in prevalence of cancer, technological advancements in healthcare sector, easy availability of pain therapeutics, and availability of premiere chemotherapy treatment options. However, Asia-Pacific is expected to register highest CAGR of 6.0% from 2021 to 2030, owing to rapid rise in the prevalence of cancer, rise in geriatric population, and increase in awareness related to early screening of cancer.
Get more information on this report : Request Sample Pages
List Of Key Companies
Key Benefits For Stakeholders
Key Market Segments
By Drug Type
By Disease Indication
By Region
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five force analysis
3.4.Top player positioning, 2020
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Rise in incidence of cancer across the globe
3.5.1.2.Surge in global geriatric population
3.5.1.3.Increase in healthcare expenditure worldwide
3.5.2.Restraint
3.5.2.1.Adverse effects associated with the use of drugs employed in cancer pain management
3.5.3.Opportunities
3.5.3.1.Increase in number of pipeline drugs
3.5.3.2.Growth opportunities in emerging markets
3.5.4.Impact analyses
3.6.COVID-19 impact analysis on cancer pain Market56
CHAPTER 4:CANCER PAIN MARKET, BY DRUG TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.Opioids
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by type
4.2.2.1.Morphine
4.2.2.1.1.Market size and forecast
4.2.2.2.Fentanyl
4.2.2.2.1.Market size and forecast
4.2.2.3.Others
4.2.2.3.1.Market size and forecast
4.2.3.Market size and forecast, by region
4.2.4.Market analysis, by country
4.3.Non-opioids
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by type
4.3.2.1.Acetaminophen
4.3.2.1.1.Market size and forecast
4.3.2.2.Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
4.3.2.2.1.Market size and forecast
4.3.3.Market size and forecast, by region
4.3.4.Market analysis, by country
4.4.Nerve blockers
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country
CHAPTER 5:CANCER PAIN MARKET, BY DISEASE INDICATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Lung cancer
5.2.1.Market size and forecast
5.2.2.Market analysis, by country
5.3.Colorectal cancer
5.3.1.Market size and forecast
5.3.2.Market analysis, by country
5.4.Breast cancer
5.4.1.Market size and forecast
5.4.2.Market analysis, by country
5.5.Prostate cancer
5.5.1.Market size and forecast
5.5.2.Market analysis, by country
5.6.Blood cancer
5.6.1.Market size and forecast
5.6.2.Market analysis, by country
5.7.Others
5.7.1.Market size and forecast
5.7.2.Market analysis, by country
CHAPTER 6:CANCER PAIN MARKET, BY REGION
6.1.Overview
6.1.1.Market size and forecast
6.2.North America
6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market size and forecast, by country
6.2.2.1.U.S.
6.2.2.1.1.U.S. market size and forecast, by type
6.2.2.1.2.U.S. market size and forecast, by disease indication
6.2.2.2.Canada
6.2.2.2.1.Canada market size and forecast, by type
6.2.2.2.2.Canada market size and forecast, by disease indication
6.2.2.3.Mexico
6.2.2.3.1.Mexico market size and forecast, by type
6.2.2.3.2.Mexico market size and forecast, by disease indication
6.2.3.Market size and forecast, by type
6.2.4.Market size and forecast, by disease indication
6.3.Europe
6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast, by country
6.3.2.1.Germany
6.3.2.1.1.Germany market size and forecast, by type
6.3.2.1.2.Germany market size and forecast, by disease indication
6.3.2.2.France
6.3.2.2.1.France market size and forecast, by type
6.3.2.2.2.France market size and forecast, by disease indication
6.3.2.3.UK
6.3.2.3.1.UK market size and forecast, by type
6.3.2.3.2.UK market size and forecast, by disease indication
6.3.2.4.Italy
6.3.2.4.1.Italy market size and forecast, by type
6.3.2.4.2.Italy market size and forecast, by disease indication
6.3.2.5.Spain
6.3.2.5.1.Spain market size and forecast, by type
6.3.2.5.2.Spain market size and forecast, by disease indication
6.3.2.6.Rest of Europe
6.3.2.6.1.Rest of Europe market size and forecast, by type
6.3.2.6.2.Rest of Europe market size and forecast, by disease indication
6.3.3.Market size and forecast, by type
6.3.4.Market size and forecast, by disease indication
6.4.Asia-Pacific
6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Market size and forecast, by country
6.4.2.1.Japan
6.4.2.1.1.Japan market size and forecast, by type
6.4.2.1.2.Japan market size and forecast, by disease indication
6.4.2.2.China
6.4.2.2.1.China market size and forecast, by type
6.4.2.2.2.China market size and forecast, by disease indication
6.4.2.3.Australia
6.4.2.3.1.Australia market size and forecast, by type
6.4.2.3.2.Australia market size and forecast, by disease indication
6.4.2.4.India
6.4.2.4.1.India market size and forecast, by type
6.4.2.4.2.India market size and forecast, by disease indication
6.4.2.5.Rest of Asia-Pacific
6.4.2.5.1.Rest of Asia- Pacific market size and forecast, by type
6.4.2.5.2.Rest of Asia- Pacific market size and forecast, by disease indication
6.4.3.Market size and forecast, by type
6.4.4.Market size and forecast, by disease indication
6.5.LAMEA141
6.5.1.Key market trends, growth factors, and opportunities
6.5.2.Market size and forecast, by country
6.5.2.1.Brazil
6.5.2.1.1.Brazil market size and forecast, by type
6.5.2.1.2.Brazil market size and forecast, by disease indication
6.5.2.2.Saudi Arabia
6.5.2.2.1.Saudi Arabia market size and forecast, by type
6.5.2.2.2.Saudi Arabia market size and forecast, by disease indication
6.5.2.3.South Africa
6.5.2.3.1.South Africa market size and forecast, by type
6.5.2.3.2.South Africa market size and forecast, by disease indication
6.5.2.4.Rest of LAMEA
6.5.2.4.1.Rest of LAMEA market size and forecast, by type
6.5.2.4.2.Rest of LAMEA market size and forecast, by disease indication
6.5.3.Market size and forecast, by type
6.5.4.Market volume and forecast, by disease indication
CHAPTER 7:COMPANY PROFILES153
7.1.AOXING PHARMACEUTICAL COMPANY, INC.
7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product Portfolio
7.2.BIODELIVERY SCIENCES INTERNATIONAL, INC.
7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product Portfolio
7.2.5.Business performance
7.2.6.Key strategic moves and developments
7.3.CK LIFE SCIENCES (WEX PHARMACEUTICALS).
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product Portfolio
7.3.5.Business performance
7.4.DAIICHI SANKYO CO., LTD.
7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product Portfolio
7.4.5.Business performance
7.4.6.Key strategic moves and developments
7.5.GRÜNENTHAL PHARMA GmbH & CO. KG
7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Product Portfolio
7.5.4.Key strategic moves and developments
7.6.HISAMITSU PHARMACEUTICAL CO., INC.
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.6.6.Key strategic moves and developments
7.7.MUNDIPHARMA INTERNATIONAL LIMITED
7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Product Portfolio
7.7.4.Key strategic moves and developments
7.8.OREXO AB
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product Portfolio
7.8.5.Business performance
7.9.PFIZER INC.
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product Portfolio
7.9.5.Business performance
7.10.TEVA PHARMACEUTICAL INDUSTRIES LIMITED
7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product Portfolio
7.10.5.Business performance
LIST OF TABLES
TABLE 01.GLOBAL CANCER PAIN MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 02.OPIOIDS MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 03.OPIOIDS MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 04.NON-OPIOIDS MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 05.NON-OPIOIDS MARKET, BY REGION, 2017–2025 ($MILLION)
TABLE 06.NERVE BLOCKERS MARKET, BY REGION, 2017–2025 ($MILLION)
TABLE 07.GLOBAL CANCER PAIN MARKET, BY DISEASE INDICATION, 2020–2030 ($MILLION)
TABLE 08.LUNG CANCER PAIN MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 09.COLORECTAL CANCER PAIN MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 10.BREAST CANCER PAIN MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 11.PROSTATE CANCER PAIN MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 12.BLOOD CANCER PAIN MARKET, BY REGION, 2020–2030 ($MILLION)92
TABLE 13.CANCER PAIN MARKET FOR OTHER DISEASE INDICATION, BY REGION, 2017–2025 ($MILLION)
TABLE 14.CANCER PAIN MARKET REVENUE, BY REGION, 2020–2030 ($MILLION)
TABLE 15.NORTH AMERICA CANCER PAIN MARKET REVENUE, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 16.U.S. CANCER PAIN MARKET, BY TYPE, 2020–2030 ($MILLION)1
TABLE 17.U.S. CANCER PAIN MARKET, BY DISEASE INDICATION, 2020–2030 ($MILLION)
TABLE 18.CANADA CANCER PAIN MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 19.CANADA CANCER PAIN MARKET, BY DISEASE INDICATION, 2020–2030 ($MILLION)
TABLE 20.MEXICO CANCER PAIN MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 21.MEXICO CANCER PAIN MARKET, BY DISEASE INDICATION, 2020–2030 ($MILLION)
TABLE 22.NORTH AMERICA CANCER PAIN MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 23.NORTH AMERICA CANCER PAIN MARKET, BY DISEASE INDICATION, 2020–2030 ($MILLION)
TABLE 24.EUROPE CANCER PAIN MARKET REVENUE, BY COUNTRY, 2021–2030 ($MILLION)
TABLE 25.GERMANY CANCER PAIN MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 26.GERMANY CANCER PAIN MARKET, BY DISEASE INDICATION, 2020–2030 ($MILLION)
TABLE 27.FRANCE CANCER PAIN MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 28.FRANCE CANCER PAIN MARKET, BY DISEASE INDICATION, 2020–2030 ($MILLION)
TABLE 29.UK CANCER PAIN MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 30.UK CANCER PAIN MARKET, BY DISEASE INDICATION, 2020–2030 ($MILLION)
TABLE 31.ITALY CANCER PAIN MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 32.ITALY CANCER PAIN MARKET, BY DISEASE INDICATION, 2020–2030 ($MILLION)
TABLE 33.SPAIN CANCER PAIN MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 34.SPAIN CANCER PAIN MARKET, BY DISEASE INDICATION, 2020–2030 ($MILLION)
TABLE 35.REST OF EUROPE CANCER PAIN MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 36.REST OF EUROPE CANCER PAIN MARKET, BY DISEASE INDICATION, 2020–2030 ($MILLION)
TABLE 37.EUROPE CANCER PAIN MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 38.EUROPE CANCER PAIN MARKET, BY DISEASE INDICATION, 2020–2030 ($MILLION)
TABLE 39.ASIA-PACIFIC CANCER PAIN MARKET REVENUE, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 40.JAPAN CANCER PAIN MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 41.JAPAN CANCER PAIN MARKET, BY DISEASE INDICATION, 2020–2030 ($MILLION)
TABLE 42.CHINA CANCER PAIN MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 43.CHINA CANCER PAIN MARKET, BY DISEASE INDICATION, 2020–2030 ($MILLION)
TABLE 44.AUSTRALIA CANCER PAIN MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 45.AUSTRALIA CANCER PAIN MARKET, BY DISEASE INDICATION, 2020–2030 ($MILLION)
TABLE 46.INDIA CANCER PAIN MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 47.INDIA CANCER PAIN MARKET, BY DISEASE INDICATION, 2020–2030 ($MILLION)
TABLE 48.REST OF ASIA-PACIFIC CANCER PAIN MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 49.REST OF ASIA-PACIFIC CANCER PAIN MARKET, BY DISEASE INDICATION, 2020–2030 ($MILLION)
TABLE 50.ASIA-PACIFIC CANCER PAIN MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 51.ASIA-PACIFIC CANCER PAIN MARKET, BY DISEASE INDICATION, 2020–2030 ($MILLION)
TABLE 52.LAMEA CANCER PAIN MARKET REVENUE, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 53.BRAZIL CANCER PAIN MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 54.BRAZIL CANCER PAIN MARKET, BY DISEASE INDICATION, 2020–2030 ($MILLION)
TABLE 55.SAUDI ARABIA CANCER PAIN MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 56.SAUDI ARABIA CANCER PAIN MARKET, BY DISEASE INDICATION, 2020–2030 ($MILLION)
TABLE 57.SOUTH AFRICA CANCER PAIN MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 58.SOUTH AFRICA CANCER PAIN MARKET, BY DISEASE INDICATION, 2020–2030 ($MILLION)
TABLE 59.REST OF LAMEA CANCER PAIN MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 60.REST OF LAMEA CANCER PAIN MARKET, BY DISEASE INDICATION, 2020–2030 ($MILLION)
TABLE 61.LAMEA CANCER PAIN MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 62.LAMEA CANCER PAIN MARKET, BY DISEASE INDICATION, 2020–2030 ($MILLION)
TABLE 63.AOXING PHARM: COMPANY SNAPSHOT
TABLE 64.AOXING PHARM: OPERATING SEGMENTS
TABLE 65.AOXING PHARM: PRODUCT PORTFOLIO
TABLE 66.BDSI: COMPANY SNAPSHOT
TABLE 67.BDSI: OPERATING SEGMENTS
TABLE 68.BDSI: PRODUCT PORTFOLIO
TABLE 69.CK LIFE SCIENCES: COMPANY SNAPSHOT
TABLE 70.CK LIFESCIENCES: OPERATING SEGMENTS
TABLE 71.CK LIFESCIENCES: PRODUCT PORTFOLIO
TABLE 72.DAIICHI SANKYO: COMPANY SNAPSHOT
TABLE 73.DAIICHI SANKYO: OPERATING SEGMENTS
TABLE 74.DAIICHI SANKYO: PRODUCT PORTFOLIO
TABLE 75.GRÜNENTHAL: COMPANY SNAPSHOT
TABLE 76.GRÜNENTHAL: PRODUCT PORTFOLIO
TABLE 77.HISAMITSU PHARMACEUTICAL: COMPANY SNAPSHOT
TABLE 78.HISAMITSU PHARMACEUTICAL: OPERATING SEGMENTS
TABLE 79.HISAMITSU PHARMACEUTICAL: PRODUCT PORTFOLIO
TABLE 80.MUNDIPHARMA: COMPANY SNAPSHOT
TABLE 81.MUNDIPHARMA: PRODUCT PORTFOLIO
TABLE 82.OREXO: COMPANY SNAPSHOT
TABLE 83.OREXO: OPERATING SEGMENTS
TABLE 84.OREXO: PRODUCT PORTFOLIO
TABLE 85.PFIZER: COMPANY SNAPSHOT
TABLE 86.PFIZER: OPERATING SEGMENTS
TABLE 87.PFIZER: PRODUCT PORTFOLIO
TABLE 88.TEVA: COMPANY SNAPSHOT
TABLE 89.TEVA: OPERATING SEGMENTS
TABLE 90.TEVA: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.CANCER PAIN MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018–2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018–2021
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018–2021
FIGURE 06.HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.HIGH THREAT OF SUBSTITUTES
FIGURE 09.HIGH THREAT OF NEW ENTRANTS
FIGURE 10.HIGH INTENSITY OF RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.IMPACT ANALYSES
FIGURE 13.MORPHINE MARKET FOR CANCER PAIN, 2020–2030 ($MILLION)
FIGURE 14.FENTANYL MARKET FOR CANCER PAIN, 2020–2030 ($MILLION)
FIGURE 15.OTHERS MARKET FOR CANCER PAIN, 2020–2030 ($MILLION)
FIGURE 16.COMPARATIVE ANALYSIS OF OPIOIDS MARKET, BY COUNTRY, 2020 & 2030 (%)
FIGURE 17.ACETAMINOPHEN MARKET FOR CANCER PAIN, 2020–2030 ($MILLION)
FIGURE 18.NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET FOR CANCER PAIN, 2020–2030 ($MILLION)
FIGURE 19.COMPARATIVE ANALYSIS OF NON-OPIOIDS, MARKET, BY COUNTRY, 2020 & 2030 (%)
FIGURE 20.COMPARATIVE ANALYSIS OF NERVE BLOCKERS MARKET, BY COUNTRY, 2020 & 2030 (%)
FIGURE 21.COMPARATIVE ANALYSIS OF LUNG CANCER PAIN MARKET, BY COUNTRY, 2020 & 2030 (%)
FIGURE 22.COMPARATIVE ANALYSIS OF COLORECTAL CANCER PAIN MARKET, BY COUNTRY, 2020 & 2030 (%)
FIGURE 23.COMPARATIVE ANALYSIS OF BREAST CANCER PAIN MARKET, BY COUNTRY, 2020 & 2030 (%)
FIGURE 24.COMPARATIVE ANALYSIS OF PROSTATE CANCER PAIN MARKET, BY COUNTRY, 2020 & 2030 (%)
FIGURE 25.COMPARATIVE ANALYSIS OF BLOOD CANCER PAIN MARKET, BY COUNTRY, 2020 & 2030 (%)
FIGURE 26.COMPARATIVE ANALYSIS OF CANCER PAIN MARKET FOR OTHER INDICATION MARKET, BY COUNTRY, 2020 & 2030 (%)
FIGURE 27.BDSI: NET SALES, 2018–2020 ($MILLION)
FIGURE 28.CK LIFE SCIENCES: NET SALES, 2018–2020 ($MILLION)
FIGURE 29.CK LIFE SCIENCES: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 30.CK LIFE SCIENCES: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 31.DACIIHI SANKYO: NET SALES, 2019–2021 ($MILLION)1
FIGURE 32.DAIICHI SANKYO: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 33.HISAMITSU PHARMACEUTICAL REVENUE, 2017–2019 ($MILLION)
FIGURE 34.HISAMITSU PHARMACEUTICAL: REVENUE SHARE BY BUSINESS SEGMENT, 2020 (%)
FIGURE 35.HISAMITSU PHARMACEUTICAL: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 36.OREXO: REVENUE, 2018–2020 ($MILLION)
FIGURE 37.OREXO: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 38.OREXO: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 39.PFIZER: REVENUE, 2018–2020 ($MILLION)
FIGURE 40.PFIZER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 41.PFIZER: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 42.TEVA: REVENUE, 2018–2020 ($MILLION)
FIGURE 43.TEVA: REVENUE SHARE BY REGION, 2020 (%)
According to analyst perspective, the cancer pain market is expected to witness a steady growth in the future. The market has drawn the interest of the healthcare industry, owing to increase in the prevalence of cancer across the world and rise in demand for ideal therapeutics for the management of cancer pain. In addition, rise in incidence of cancer, surge in R&D studies to develop ideal cancer pain therapeutics, wide availability of drugs for management of cancer pain and growth in adoption of cancer pain medications is projected to supplement the market growth during the forecast period. The cancer pain market is dominated by well-established players; hence, the market is anticipated to witness intense competition. Due to surge in use of cancer pain drugs owing to higher number of cancers affected patient population with developed healthcare infrastructure is expected to boost the market growth in the near future.
A. There is no value chain analysis provided in the cancer pain market report.
A. Yes, cancer pain market companies are profiled in the report
A. The key trends in the cancer pain market are due to rise in prevalence of cancer across geographies and increase in adoption of cancer pain drugs for treatment of mild to moderate pain drive the growth of the global cancer pain market.
A. The market value of cancer pain market in 2030 is 10,329.40 million.
A. The total market value of cancer pain market is $6,197.00 million in 2020.
A. The top companies that hold the market share in cancer pain market are Aoxing Pharmaceutical Company, Inc. Teva Pharmaceutical Industeries Limted, Inc, Pfizer, Inc and Orexo AB.
A. The base year for the report is 2020.
A. The forecast period in the report is from 2021 to 2030.
Enterprise
License/PDF
Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
